Authors: Aapro, M Rowinsky, E

Citation: M. Aapro et E. Rowinsky, Docetaxel: assessing a range of activity, ANTI-CANC D, 12, 2001, pp. S1-S3

Authors: Forastiere, AA Leong, T Rowinsky, E Murphy, BA Vlock, DR DeConti, RC Adams, GL

Citation: Aa. Forastiere et al., Phase III comparison of high-dose paclitaxel plus cisplatin plus granulocyte colony-stimulating factor versus low-dose paclitaxel plus cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393, J CL ONCOL, 19(4), 2001, pp. 1088-1095

Authors: Miller, KD Picus, J Blanke, C John, W Clark, J Shulman, LN Thornton, D Rowinsky, E Loehrer, PJ

Citation: Kd. Miller et al., Phase II study of the multitargeted antifolate LY231514 (ALIMTA (TM), MTA,pemetrexed disodium) in patients with advanced pancreatic cancer, ANN ONCOL, 11(1), 2000, pp. 101-103

Authors: Bonomi, P Kim, KM Fairclough, D Cella, D Kugler, J Rowinsky, E Jiroutek, M Johnson, D

Citation: P. Bonomi et al., Comparison of survival and quality of life in advanced non-small-cell lungcancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperativeoncology group trial, J CL ONCOL, 18(3), 2000, pp. 623-631

Authors: Rowinsky, E Raymond, E Ciardiello, F Averbuch, SD

Citation: E. Rowinsky et al., Epidermal growth factor receptor-targeted approaches for anticancer therapy: Focus on ZD1839 - Questions and answers, DRUGS, 60, 2000, pp. 41-42